Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Cafone

Pediatrics Mullica Hill, NJ Doctor of Osteopathy

NPI 1588663728 CMS profile 550389

8 High St, Suite 1B, Mullica Hill, NJ 08062

Open in the dashboard

General payments

$3,660

160 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Cafone of Mullica Hill, NJ is reported in the CMS Open Payments database as having received $3,660 across 160 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $445 15
2024 General $451 32
2023 General $785 30
2022 General $405 13
2021 General $847 36
2020 General $337 17
2019 General $391 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Cafone
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Michael Cafone were reported at $445. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Michael Cafone Pediatrics median Middle half National median
2019 $391 $86 $31–$183 $163
2020 $337 $49 $22–$110 $114
2021 $847 $68 $27–$158 $132
2022 $405 $77 $30–$173 $149
2023 $785 $88 $33–$190 $160
2024 $451 $94 $34–$206 $164
2025 $445 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Ironshore Pharmaceuticals Inc. $1,463 68 payments
  2. GlaxoSmithKline, LLC. $918 20 payments
  3. Corium, Inc. $300 16 payments
  4. Supernus Pharmaceuticals, Inc. $270 16 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $161 12 payments
  6. Tris Pharma Inc $140 10 payments
  7. Medtronic, Inc. $126 1 payment
  8. Collegium Pharmaceutical, Inc. $91 5 payments
  9. Pfizer Inc. $69 5 payments
  10. Cranial Technologies, Inc $53 3 payments
  11. Other $68 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,410 159 payments
  2. Consulting Fee $250 1 payment
Products named General payments · program years 2019–2025
  1. JORNAY PM Central Nervous System Stimulant $684 39 payments
  2. JORNAY PM Central Nervous Stimulant ADHD $584 19 payments
  3. BEXSERO $382 14 payments
  4. Azstarys $300 16 payments
  5. Jornay PM 20mg capsules (Bottle of 100) $195 10 payments
  6. QELBREE $180 12 payments
  7. PEDIARIX $167 12 payments
  8. VYVANSE $161 12 payments
  9. PENMENVY $149 3 payments
  10. MINIMED 780G $126 1 payment
  11. Other $557 36 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

160 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatrics in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record